[HTML][HTML] Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

F Tarrés-Freixas, B Clotet, J Carrillo, J Blanco - Vaccines, 2024 - mdpi.com
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III
clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of …

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

F Tarrés-Freixas, B Clotet, J Carrillo, J Blanco - Vaccines, 2024 - pubmed.ncbi.nlm.nih.gov
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III
clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of …

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.

F Tarrés-Freixas, B Clotet, J Carrillo, J Blanco - Vaccines, 2024 - europepmc.org
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III
clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of …

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.

F Tarrés-Freixas, B Clotet, J Carrillo, J Blanco - Vaccines, 2024 - search.ebscohost.com
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III
clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of …

[HTML][HTML] Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

F Tarrés-Freixas, B Clotet, J Carrillo, J Blanco - Vaccines, 2024 - ncbi.nlm.nih.gov
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III
clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of …

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.

F Tarrés-Freixas, B Clotet, J Carrillo, J Blanco - Vaccines, 2024 - europepmc.org
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III
clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of …